This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Asthma
and you are
between 18 and 70
years old
2
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

This study will compare efficacy and safety of different regimens of olodaterol administration in asthma (once daily, twice daily) with placebo in a complete cross-over design each within one of the two daily dose groups (medium or high daily dose).

Provided treatments

  • Drug: Placebo twice daily
  • Drug: Olodaterol low daily dose twice daily
  • Drug: Olodaterol medium daily dose twice daily
  • Drug: Placebo twice daily
  • Drug: Olodaterol high daily dose once daily and placebo
  • Drug: Olodaterol medium daily dose once daily and placebo

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01311661. The sponsor of the trial is Boehringer Ingelheim and it is looking for 206 volunteers for the current phase.
Official trial title:
Phase II, Randomised, Double-Blind, Cross-over Study to Compare the 24-hour FEV1-time Profile of Orally Inhaled Olodaterol, Delivered With the Respimat® Inhaler, After 3 Weeks of Olodaterol Once Daily Medium Dose, Twice Daily Low Dose and Placebo or After 3 Weeks of Once Daily High Dose, Twice Daily Medium Dose and Placebo Administration in Patients With Moderate to Severe Persistent Asthma